Referral of newly diagnosed adolescent patients with acute lymphoblastic leukemia to pediatric and National Cancer Institute-designated centers should be strongly recommended.
A continuing medical education session at the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer offered insight for optimal selection and administration of PARP inhibitors, as well as homologous recombination deficiency testing in ovarian cancer.
Rebecca Kirch, JD, executive vice president, Healthcare Quality & Value, National Patient Advocate Foundation, explains the value of palliative care in the context of the triple aim.
A new study compared medical care cost estimates of different cancer types for patients aged at least 18 years and provided important evidence about the cost of cancer care across the age spectrum.
A study presented at the European Lung Cancer Congress investigated the effects of multiple therapies on symptom management in ALK-positive non-small cell lung cancer.
Robert M Rifkin, MD, FACP, gave an update on the basics, education, and reimbursement of biosimilars, stating that “this will be a huge year” for the the copycat biologics in the United States.
Debra Patt, MD, MPH, MBA, spoke about the major issues affecting patients with cancer and community practices in the United States.
Lucio N Gordan, MD, shared a variety of data suggesting that the general trend of cancer therapy being moved from the community setting to the hospital outpatient setting has resulted in significant cost increases.
The National Comprehensive Cancer Network announced its intent to broaden the use of the Shared Resource Database to all cancer centers within the United States.
A panel at the SGO 2018 Annual Meeting on Women’s Cancer convened to achieve consensus on PARP inhibitor use for the treatment and maintenance of ovarian cancer in the context of current standards.